Acquired resistance to the EGFR tyrosine kinase inhibitor (TKI) in NSCLC patients is correlated with overexpression of osteopontin (OPN), upregulation of integrin αVβ3, and activation of downstream signaling pathways such as FAK/AKT and ERK (13). This evidence concerns the gene EGFR and non-small cell lung carcinoma.